Please login first

Biomedicines Webinar | Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

Part of the MDPI Biomedicines Webinars series
7 Feb 2023, 14:00 (CET)

Renal Cell Carcinoma, Pathology, Physiology, Diagnosis, Multimodal Treatment, Drug Resistance, Biomarkers
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Event Registration Contact Us

Welcome from the Chairs

5th Biomedicines Webinar

Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

Dear colleagues,

We are pleased to announce the upcoming webinar “Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches”, which will be held on Tuesday, February 7, 2023, at 2:00-3:15 pm CET.

Renal cell carcinoma is a complex disease comprised of a variety of histological subtypes. This webinar focuses on recent advances on clinicopathological, physiological, and molecular approaches to the diagnosis, classification, and novel multidisciplinary treatment of renal cell carcinoma.

The recently published fifth edition of the WHO classification for renal cell carcinoma contains significant revisions. In this webinar, two pathologists will present overviews of the latest advances in the pathology of renal cell carcinomas with papillary features and oncocytic and chromophobe renal tumors, including emerging/provisional entities and those relevant molecular aspects. A Urologist will present recent medical therapy for advanced or metastatic renal cell carcinoma. The speakers will each speak for approximately 15 minutes, and then we will open it up to questions from the audience and discussion. Please join us live for this webinar and contribute to the discussion.

Dr. Silvio Maringhini
Dr. Riuko Ohashi

Date: 7 February 2023

Time: 2:00 pm CET | 8:00 am EST | 9:00 pm CST Asia

Webinar ID: 863 9563 8016

Webinar Secretariat:


Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, 90127 Palermo, Italy

Dr. Silvio Maringhini received his Medical Doctor from University of Palermo in 1975; He acted as Director, Pediatric Nephrology Unit, Children’s Hospital, Palermo, Italy from 1995 to 2017. 2018-present, he is Consultant Nephrologist, ISMETT, Palermo. Memberships: International Association of Pediatric Nephrology, European Society of Paediatric Nephrology (President of the 2006 Meeting, Chair Working Group “CAKUT, Urinary Tract Infections, Bladder Disorders), Società Italiana di Nefrologia, Società Italiana di Nefrologia Pediatrica (Past President).

Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Japan

Dr. Riuko Ohashi is an associate professor of pathology at the Niigata University, Japan. She received her MD from the Hamamatsu University School of Medicine in 2001, her doctorate degree from the Niigata University in 2015, and had postdoctoral experience at the Department of Pathology and Molecular Pathology, University Hospital Zurich (Switzerland). She has coauthored several chapters on renal cell carcinoma in the fifth edition of the World Health Organization (WHO) classification of urogenital tumours (WHO "Blue Book"), published in 2022. Her research interests include translational molecular pathology and developing a clinicopathological prognostic stratification system for renal cancer.

Invited Speakers

Department of Pathology, Portuguese Oncology Institute of Porto/Porto Comprehensive Cancer Centre (Porto.CCC), Rua Dr. António Bernardino de Almeida, Porto, Portugal,
Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Centre (Porto.CCC),
Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Portugal

João Lobo, MD, PhD, is a Pathology Resident at the Portuguese Oncology Institute of Porto (IPO Porto). He received his MD (2013) and doctorate degree (with European PhD Title, 2021) from the School of Medicine and Biomedical Sciences of University of Porto (ICBAS-UP), where he is also a Lecturer in Pathology. He is a Junior Researcher at the Cancer Biology and Epigenetics Group of IPO Porto. João has co-authored 93 original articles in peer reviewed journals (h-index=20). In 2021, João completed a fellowship in Uropathology dedicated to kidney tumors at the University Hospital Zurich (Switzerland), and co-authored several publications on papillary renal cell carcinoma. His research interests include biomarkers (in tissue and liquid biopsies) for patients with urological malignancies.

Department of Urology, Gifu University Graduate School of Medicine, Japan

Dr. Koji Iinuma is the lecturer at the Department of Urology, Gifu University, Gifu, Japan. He became the urologist in 2011 and received his M.D. degree from Gifu University in 2022. He has published various papers on urologic oncology and has recently published several papers on ICI-based combination therapies for advanced and metastatic renal cell carcinoma (mRCC). His research interests include multi-modality therapies for mRCC, including pharmacological and surgical treatments, and the investigation of biomarkers that may predict prognosis and response to the combination therapies.

Webinar Content

To view this content, you need to be registered and logged in to Sciforum platform.



Time in CET

Chairs Dr. Silvio Maringhini and Dr. Riuko Ohashi

Chairs Introduction

2:00 - 2:10 pm

Dr. João Lobo

The Morphological Spectrum of Renal Cell Tumors With Papillary Features

2:10 - 2:25 pm

Dr. Riuko Ohashi

Advances and Controversies in Oncocytic and Chromophobe Renal Tumors

2:25 - 2:40 pm

Dr. Koji Iinuma

Medical Therapy for Advanced or Metastatic Renal Cell Carcinoma

2:40 – 2:55 pm


2:55 - 3:10 pm

Closing of Webinar

Chairs Dr. Silvio Maringhini and Dr. Riuko Ohashi

3:10 - 3:15 pm

Relevant SI

Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches 2.0
Guest Editors: Dr. Silvio Maringhini and Dr. Riuko Ohashi
Deadline for manuscript submissions: 15 March 2023

Sponsors and Partners